Literature DB >> 35610512

CXCR2 inhibition in NASH-HCC.

Eleni Kotsiliti1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35610512     DOI: 10.1038/s41575-022-00637-3

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   73.082


× No keyword cloud information.
  1 in total

1.  CXCR2 inhibition enables NASH-HCC immunotherapy.

Authors:  Jack Leslie; John B G Mackey; Thomas Jamieson; Erik Ramon-Gil; Thomas M Drake; Frédéric Fercoq; William Clark; Kathryn Gilroy; Ann Hedley; Colin Nixon; Saimir Luli; Maja Laszczewska; Roser Pinyol; Roger Esteban-Fabró; Catherine E Willoughby; Philipp K Haber; Carmen Andreu-Oller; Mohammad Rahbari; Chaofan Fan; Dominik Pfister; Shreya Raman; Niall Wilson; Miryam Müller; Amy Collins; Daniel Geh; Andrew Fuller; David McDonald; Gillian Hulme; Andrew Filby; Xabier Cortes-Lavaud; Noha-Ehssan Mohamed; Catriona A Ford; Ximena L Raffo Iraolagoitia; Amanda J McFarlane; Misti V McCain; Rachel A Ridgway; Edward W Roberts; Simon T Barry; Gerard J Graham; Mathias Heikenwälder; Helen L Reeves; Josep M Llovet; Leo M Carlin; Thomas G Bird; Owen J Sansom; Derek A Mann
Journal:  Gut       Date:  2022-04-27       Impact factor: 31.793

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.